Expertise in
9
conditions

Dr. Teresa L. Rutledge

Oncology
University Of New Mexico
1 University Of New Mexico, 
Albuquerque, NM 
Expertise in
9
conditions
University Of New Mexico
1 University Of New Mexico, 
Albuquerque, NM 

Overview

Teresa Rutledge is an Oncologist practicing medicine in Albuquerque, New Mexico.

Dr. Rutledge is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Hernia Surgery, and Salpingo-Oophorectomy.

She is actively involved in clinical research, co-authoring 19 peer reviewed articles and participating in 8 clinical trials.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in NM

Hospital Affiliations

Unm Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

University of New Mexico
1 University Of New Mexico, Albuquerque, NM 87131

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: August 04, 2026
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
Stepped-Care Telehealth for Distress in Cancer Survivors
Stepped-Care Telehealth for Distress in Cancer Survivors
Enrollment Status: Completed
Publish Date: February 27, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug, Other
Study Phase: Not Applicable
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
A Phase I Study of Intraperitoneal Egen-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Pegylated Liposomal-Doxorubicin (PLD, Doxil (NSC# 712227 or Lipodox (NSC#673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I Study of Intraperitoneal Egen-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Pegylated Liposomal-Doxorubicin (PLD, Doxil (NSC# 712227 or Lipodox (NSC#673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: March 12, 2019
Intervention Type: Other, Drug, Biological
Study Phase: Phase 1
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Enrollment Status: Unknown
Publish Date: February 19, 2018
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 7 Less Clinical Trials

19 Total Publications

Developing and Implementing a Patient-Centered Opioid Prescribing Algorithm among Gynecological Oncology Patients.
Developing and Implementing a Patient-Centered Opioid Prescribing Algorithm among Gynecological Oncology Patients.
Journal: Journal of women's health (2002)
Published: May 06, 2024
Similar Doctors
Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

University Of New Mexico Ems Consortium

1 University Of New Mexico, 
Albuquerque, NM 
 (0.1 miles away)
505-925-0460
Languages Spoken:
English
See accepted insurances

Carolyn Muller is an Oncologist practicing medicine in Albuquerque, New Mexico. Dr. Muller is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, and Testicular Yolk Sac Tumor.

Expertise in
47
conditions
Expertise in
47
conditions
Referral may be required

New Mexico Cancer Center

4901 Lang Ave NE, 
Albuquerque, NM 
 (6.3 miles away)
505-842-8171
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Annette Fontaine is an Oncologist practicing medicine in Albuquerque, New Mexico. Dr. Fontaine is highly rated in 47 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, Bone Marrow Aspiration, and Salpingo-Oophorectomy. Dr. Fontaine is board certified in American Board Of Internal Medicine. Dr. Fontaine is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Office

2400 Unser Blvd SE Ste 28300, 
Rio Rancho, NM 
 (15.5 miles away)
505-843-7813
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Karen Finkelstein is an Oncologist practicing medicine in Rio Rancho, New Mexico. Dr. Finkelstein is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Malignant Mixed Mullerian Tumor, Sertoli-Leydig Cell Tumor, Hernia Surgery, and Salpingo-Oophorectomy. Dr. Finkelstein is currently accepting new patients.

Frequently Asked Questions about Dr. Teresa L. Rutledge

How do I make an appointment with Dr. Teresa L. Rutledge?

You can book an appointment with Dr. Teresa L. Rutledge by calling their office at 505-925-0461. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Teresa L. Rutledge a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Teresa L. Rutledge is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Teresa L. Rutledge specialize in?

While Dr. Teresa L. Rutledge is a Oncology, they have specific expertise in Ovarian Cancer, Ovarian Carcinosarcoma, and Sertoli-Leydig Cell Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Teresa L. Rutledge participate in research or clinical trials?

Yes. Dr. Teresa L. Rutledge has published 19 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Teresa L. Rutledge's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Teresa L. Rutledge accept my insurance?

Dr. Teresa L. Rutledge accepts most major insurance plans, including Anthem BCBS and Cigna. We recommend calling the office directly at 505-925-0461 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rutledge's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile